# US 2023/0263918 A1 · Antiviral methods and compositions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0263918 A1
- Document ID: US20230263918A1
- Status: Published application
- Kind: A1
- Application number: 18/017,813
- Filed: 2021-07-28
- Published: 2023-08-24
- Earliest claimed: 2020-07-28
- Inventors: David G. Whitten; Kirk S. Schanze; Linnea K. Ista; Patrick L. Donabedian; Eva Yung Hua Chi; Florencia A. Monge; Alison Meredith Kell
- Web page: https://patentgrep.com/patent/US20230263918A1

## CPC

- A61L 2/18: Liquid substances
- A01N 25/00: Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application {, e.g. seed treatment or sequential application}; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
- A01N 25/34: Shaped forms, e.g. sheets, not provided for in any other sub-group of this main group
- A01P 1/00: Disinfectants; Antimicrobial compounds or mixtures thereof
- A61L 2/084: Visible light
- A61L 2/085: Infrared radiation
- A61L 2/088: using photocatalysts or photosensitisers
- A61L 2/10: Ultraviolet [UV] radiation
- A61L 9/14: using sprayed or atomised substances {including air-liquid contact processes}
- A61L 9/18: Radiation (A61L9/22 takes precedence)
- A61L 9/20: Ultraviolet radiation
- A61L 9/205: {using a photocatalyst or photosensitiser}
- A01N 33/12: Quaternary ammonium compounds
- A01N 43/10: with sulfur as the ring hetero atom
- A01N 43/50: 1,3-Diazoles; Hydrogenated 1,3-diazoles
- A01N 43/90: having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
- A61L 2/22: Phase substances, e.g. smokes or aerosols
- A61L 2101/38: Ethers
- A61L 2101/40: containing sulfur
- A61L 2101/44: Heterocyclic compounds
- A61L 2101/46: Macromolecular compounds
- A61L 2103/15: Laboratory, medical or dentistry appliances, e.g. catheters or sharps
- A61L 2103/50: Textiles, e.g. bedwear or towels
- A61L 2103/75: Room floors or walls
- A61L 2202/15: Biocide distribution means, e.g. nozzles, pumps, manifolds, fans, baffles, sprayers
- A61L 2209/14: Filtering means
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A01N: PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF (preservation of food or foodstuff A23); BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES (preparations for medical, dental or toiletry purposes which kill or prevent the growth or proliferation of unwanted organisms A61K); PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01P: BIOCIDAL, PEST REPELLANT, PEST ATTRACTANT OR PLANT GROWTH REGULATORY ACTIVITY OF CHEMICAL COMPOUNDS OR PREPARATIONS

## Abstract

A method of inactivating an enveloped ssRNA virus, such as SARS-CoV-2. The method involves contacting the enveloped ssRNA virus with an antiviral polyelectrolyte compound and/or a conjugated aromatic compound effective to inactivate the virus. The disclosure also provides a method of reducing the period of viability of enveloped ssRNA virus, such as SARS-CoV-2, on personal protective equipment, in filtered air, and on surfaces that have come into contact with the virus.

## Claims

### Claim 1

A method of inhibiting an enveloped ssRNA virus, comprising contacting the virus with a composition comprising a compound having the structure of Formula I, Ib, Ic, or II in the presence of light,
wherein
each of X and Y is independently H, COOR, O—(CH2)m-T, NH2, or COR;
each of Za and Zb is independently H, O—(CH2)m-T, O—C2H4—(OCH2)m—R;
each of G1 and G2 is independently a bond, C2C6H4, C6H4, C2C4S, or C4S;
J and Q are each C or CH so as to provide a benzene ring, or J and Q are together S so as to provide a thiophene ring;
n is 1 to 200;
p is 1 to 10,000;
m is 0 to 10;
each of R is independently methyl, ethyl, n-propyl, isopropyl, phenyl, t-butyl, isobutyl, n-butyl, pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclyhexyl, methoxymethyl, or trifluoromethyl;
each of T is independently H, SO3−, COO−, COOR, DABCO, N-alkyl DABCO, imidazolyl, N-alkyl imidazolyl, NR2, NHR2+, or NR3+;
L1 is independently a bond or —C≡C—;
L2 is independently a bond, a substituted or unsubstituted phenylene, thiophenylene, azulenylene, heptalenylene, biphenylene, indacenylene, fluorenylene, phenanthrenylene, triphenylenylene, pyrenylene, naphthacenylene, chrysenylene, biphenylenylene, anthracenylene, and naphthylene;
L3 is independently a bond or —C≡C—;
each of W, if present, can independently be a bond, —C═C—, or —C═C—; and
at least one occurrence of Y, X, Za, and Zb is independently O—(CH2)m-T.

### Claim 2 (depends on 1)

The method of claim 1, wherein the enveloped ssRNA virus is SARS-CoV-2.

### Claim 3 (depends on 1)

The method of claim 1, wherein the contacting is in the presence of visible light or UV light.

### Claim 4 (depends on 1)

The method of claim 1, wherein the compound has a molecular weight of less than 2000 Da.

### Claim 5 (depends on 1)

The method of claim 1, wherein the compound has the structure of formula I and n=1.

### Claim 6 (depends on 1)

The method of claim 1, wherein the compound has the structure of Formula II, and wherein:
each of X and Y is independently H or COOR;
each of Za is O—(CH2)m-T;
G1 is C6H4;
G2 is a bond:
J and Q are each CH so as to provide a benzene ring;
n is 1;
p is 1 to 10,000;
m is 2 to 3;
each of R is methyl or ethyl;
each of T is SO3−, N-hexyl DABCO, or N-methyl imidazolyl;
L1 is —C≡C—;
L2 is unsubstituted phenylene; and
L3 is —C≡C—.

### Claim 7 (depends on 1)

The method of claim 1, wherein the method is a method of reducing SARS-CoV-2 viability on a substrate, the method further comprising treating a substrate with the composition and exposing the substrate to SARS-CoV-2 in the presence of light.

### Claim 8 (depends on 1)

The method of claim 1, wherein the substrate is a wipe, a tissue, a bandage, a medical device, a surgical instrument, a sponge, a textile, a diaper, a counter-top, a food preparation surface, a wound dressing, a dressing for surgical incisions, a keyboard surface, a packing for wounds, a packing for surgical incisions, a nasal packing, a feminine care product, a fabric, a work surface, a medical device, packaging materials, personal protective equipment, a water filter, an air filter, a mask, or a combination thereof.

### Claim 9 (depends on 1)

The method of claim 1, wherein the compound has the structure of Formula V
wherein X is n-hexyl DABCO, n-methyl imidazolium, or trimethylammonium.

### Claim 10 (depends on 1)

The method of claim 1, wherein the compound has the structure:

### Claim 11 (depends on 1)

The method of claim 1, wherein the compound has the structure:

### Claim 12 (depends on 1)

The method of claim 1, wherein the compound has the structure:

### Claim 13 (depends on 1)

The method of claim 1, wherein the compound has the structure:

### Claim 14 (depends on 1)

The method of claim 1, wherein the compound has the structure:
wherein m and n are each independently 1 to 10.

### Claim 15 (depends on 1)

The method of claim 1, wherein the compound has a structure selected from the group consisting of:

### Claim 16

A method of inhibiting SARS-CoV-2, comprising:
treating a substrate surface with a composition comprising a compound having the structure of Formula I, Ib, Ic, or II,
wherein
each of X and Y is independently H, COOR, O—(CH2)m-T, NH2, or COR;
each of Za and Zb is independently H, O—(CH2)m-T, O—C2H4—(OCH2)m—R;
each of G1 and G2 is independently a bond, C2C6H4, C6H, C2C4S, or C4S;
J and Q are each C or CH so as to provide a benzene ring, or J and Q are together S so as to provide a thiophene ring;
n is 1 to 200;
p is 1 to 10,000;
m is 0 to 10;
each of R is independently methyl, ethyl, n-propyl, isopropyl, phenyl, t-butyl, isobutyl, n-butyl, pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclyhexyl, methoxymethyl, or trifluoromethyl;
each of T is independently H, SO3−, COO−, COOR, DABCO, N-alkyl DABCO, imidazolyl, N-alkyl imidazolyl, NR2, NHR2+, or NR3+;
L1 is independently a bond or —C≡C—;
L2 is independently a bond, a substituted or unsubstituted phenylene, thiophenylene, azulenylene, heptalenylene, biphenylene, indacenylene, fluorenylene, phenanthrenylene, triphenylenylene, pyrenylene, naphthacenylene, chrysenylene, biphenylenylene, anthracenylene, and naphthylene;
L3 is independently a bond or —C≡C—;
each of W, if present, can independently be a bond, —C≡C—, or —C≡C—; and
at least one occurrence of Y, X, Za, and Zb is independently O—(CH2)m-T.

### Claim 17 (depends on 16)

The method of claim 16, wherein the method is a method of inhibiting SARS-CoV-2 in circulated air, wherein the substrate surface comprises an air filter.

### Claim 18

A method of inactivating SARS-CoV-2 virus, the method comprising:
contacting SARS-CoV-2 virus with a conjugated aromatic compound effective to inactivate the virus.

### Claim 19 (depends on 18)

The method of claim 18, wherein the conjugated aromatic compound comprises the structure:
or wherein the conjugated aromatic compound has the structure:
wherein
n is 1 to 10,000,
at each occurrence, j is independently 1 or 2,
RA is —H or RC,
at each occurrence, RB is independently —H or RC,
RC is —X—R1-R2,
X is a bond, —O—, —NH—, or —S—,
R1 is substituted or unsubstituted (C1-C20)alkylene,
R2 is -(1,4-substituted 1,4-diazabicyclo[2.2.2]octane-1,4-diium)-R3, 3-R3-substituted imidazolium, pyridinium, —SO3−, —CO2H, —CO2−, —N+(R3)3, —N+(R3)2H, or —N(R3)2,
R3 is —H or substituted or unsubstituted (C1-C10)alkane, and
at least one RA or RB in the compound is RC.

### Claim 20 (depends on 18)

The method of claim 18, wherein the conjugated aromatic compound comprises the structure:
